Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Lymphedema, Secondary
Interventions: TDC; Diagnostic Test
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
Interventions: Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine; Procedure · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Lomvastomig; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications, Radiation Toxicity, Urinary Complications, Urinary Tract Toxicity
Interventions: Standard radiation therapy, intensity-modulated radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 129
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 106 more

Conditions: Uterine Cervical Neoplasms
Interventions: BD Onclarity™ HPV assay on BD Viper™ LT, Colposcopy; Device · Procedure
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 33,858 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more

Conditions: Cancer, Solid Tumor
Interventions: CALAA-01; Drug
Lead sponsor: Calando Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • San Antonio, Texas

Conditions: Head and Neck Cancer
Interventions: AMD3100, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: CPI-613; Drug
Lead sponsor: Cornerstone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Squamous Cell Carcinoma of the Oropharynx
Interventions: ISA101b; Drug
Lead sponsor: ISA Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 5 more

Conditions: Head and Neck Cancer
Interventions: paclitaxel; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 20
States / cities: Fresno, California • Loma Linda, California • Hollywood, Florida + 17 more

Conditions: Head and Neck Cancer
Interventions: Questionnaires, Acupuncture, Electroencephalogram (EEG); Behavioral · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region
Interventions: MRgART, LINAC; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Uterine Cervical Neoplasms, Ovarian Neoplasms, Gynecologic Neoplasms, Fallopian Tube Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Peritoneal Neoplasms
Interventions: Specialized Symptom Management and Supportive Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer
Interventions: Questionnaire, Patient Navigator (PN); Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 2,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Obstructive Pulmonary Disease, Lung Cancer, Head and Neck Cancer
Interventions: Observational Phase 1, Observational Phase 2, Group I, Observational Phase 2, Group II, Observational Phase 3; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Cetuximab, Cisplatin, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Biological · Drug · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Venous Thromboembolism, Head and Neck Cancer
Interventions: Enoxaparin, Apixaban; Drug
Lead sponsor: Kiranya Arnold; Other
Eligibility: 18 Years to 89 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Head and Neck Neoplasm
Interventions: 50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy, Concurrent Atezolizumab, Adjuvant Atezolizumab; Radiation · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell Carcinoma
Interventions: Lidocaine 1% Injectable Solution; Drug
Lead sponsor: Ryan Carey; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Esophageal Cancer, Esophageal Carcinoma
Interventions: Exercise and Nutrition, Usual Care Group; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Esophageal Cancer
Interventions: Telephone Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Carcinoma, Endometrial Carcinoma, Malignant Female Reproductive System Neoplasm, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer, Esophageal Neoplasms
Interventions: Prehabilitation Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Skin Biophysical Measures for Assessing Head and Neck Cancer-Related External Lymphedema

Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia

HEARTS Trial for Thoracic Cancers

Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

COPD Care Pathway Among Patients With Cancer

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)

Quality of Life After Esophagectomy for Cancer

Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer

Esophageal Cancer Multimodal Prehabilitation Study